TNM-9 Staging Shows Limited Prognostic Accuracy in Nasopharyngeal Carcinoma

The management of nasopharyngeal carcinoma has evolved significantly with the integration of intensity-modulated radiotherapy and multimodal systemic regimens [1, 2]. While the tumor-node-metastasis (TNM) framework remains the standard for clinical decision-making, the emergence of high-sensitivity imaging and molecular biomarkers has challenged traditional anatomical staging [3, 4]. Clinicians increasingly rely on advanced diagnostics to identify patients at high risk for distant failure, yet the prognostic accuracy of these staging systems must be continuously validated against modern imaging standards [5, 6]. As the transition to newer staging editions occurs, understanding how these updates perform in the context of current diagnostic technologies is essential for optimizing patient outcomes. A recent study now evaluates the clinical utility of the latest staging updates in the era of advanced metabolic imaging.